GC Green Cross announced on June 11 that it presented its mRNA vaccine development strategy for future pandemic responses at the "Seoul Pandemic X Summit 2026."
During the event, the company revealed its proprietary mRNA-LNP platform and the current status of its COVID-19 vaccine development. Since 2019, GC Green Cross has been researching an AI deep learning-based mRNA-LNP platform. The company has developed capabilities for mRNA sequence design that maximizes protein expression efficiency through codon optimization software, and has enhanced delivery efficiency with optimized LNP lipid structures and compositions.
The COVID-19 mRNA vaccine candidates being developed on this platform have shown immune responses comparable to global vaccines in preclinical studies, and their safety has been confirmed. Additionally, the company has established a complete in-house process from cell line development to mRNA synthesis, LNP formulation, final product manufacturing, and quality analysis.
The mRNA vaccine platform is considered a versatile technology that can rapidly respond to new pathogens and variants, not limited to specific infectious diseases. The ability to independently develop and produce mRNA vaccines in South Korea is seen as a key element of vaccine sovereignty, ensuring stable access to vaccines amid global supply chain uncertainties.
"We will strengthen our pandemic response capabilities based on our mRNA research capabilities and production infrastructure," said Jeong Jae-wook, head of R&D at GC Green Cross.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.